Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.8 million
Deal Type : Private Placement
Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement
Details : Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associa...
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 07, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.8 million
Deal Type : Private Placement